Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
Rhea-AI Summary
Accuray (NASDAQ: ARAY) appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will lead global commercial strategy across sales, marketing, pricing, market access, partnerships and launch excellence as the company pursues improved commercial execution and growth.
He joins with nearly two decades of global capital-medical device experience and a track record of reversing revenue declines and generating double-digit annual sales growth in prior roles.
Positive
- Appointment effective April 6, 2026
- Global commercial leader with nearly 20 years experience
- Proven track record: double-digit annual sales growth in prior role
- Responsibility for sales, marketing, pricing, market access, partnerships
Negative
- None.
News Market Reaction – ARAY
In the Apr 6 session, ARAY gained 0.84%, reflecting a mild positive market reaction. Argus tracked a trough of -14.9% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Q2 2026 earnings | Negative | -20.7% | Revenue decline, margin compression, net loss and restructuring charges disclosed. |
| Jan 21 | Earnings date set | Neutral | +2.5% | Announcement of timing and logistics for upcoming Q2 earnings call. |
| Dec 15 | Transformation plan | Positive | -2.9% | Cost-cutting, realignment, and ~15% headcount reduction targeting profitability. |
| Nov 05 | Q1 2026 earnings | Negative | -15.9% | Lower revenue, larger net loss, restructuring charges, and backlog decline reported. |
| Oct 31 | CEO equity awards | Neutral | -0.7% | Inducement RSUs and performance-based stock units for new CEO under NASDAQ rules. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings and transformation updates have often been followed by negative price reactions, while scheduling/administrative news produced smaller, mixed moves.
Over the last six months, Accuray has focused on restructuring and leadership changes. Fiscal 2026 Q1 and Q2 earnings on Nov 5, 2025 and Feb 4, 2026 showed revenue declines, margin pressure, and restructuring charges, with shares falling 15.86% and 20.68% after those reports. A transformation plan on Dec 15, 2025 targeting about $25M in annualized profitability improvement and a ~15% headcount reduction drew a modest negative reaction. An inducement equity award for the new CEO on Oct 31, 2025 and the Q2 earnings-date announcement had relatively small price moves.
Key Terms
radiation therapy medical
neuro-radiosurgery medical
forward-looking statements regulatory
Form 10-Q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
"Paul brings deep global commercial leadership experience and a strong track record of driving transformation and sales growth in complex medical technology businesses," said Steve La Neve, President and Chief Executive Officer of Accuray. "His background in rebuilding commercial operating models, accelerating capital equipment and services sales, and unlocking recurring revenue opportunities will be instrumental as we continue to strengthen our commercial performance and position Accuray for long‑term value creation."
Mr. Miele is a seasoned commercial executive with nearly two decades of experience leading and scaling global capital medical device businesses across the
As Chief Commercial Officer, Mr. Miele will be responsible for defining and executing Accuray's global commercialization strategy across sales, marketing, pricing and market access, commercial partnerships, and launch excellence.
"Accuray has a strong foundation of innovation, a large installed base, a group of dedicated distribution partners, and a meaningful opportunity to further strengthen its commercial impact worldwide," said Paul Miele. "Most importantly, Accuray's products are vital to treating cancer patients in 70+ countries around the world. I'm excited to join the team and help drive growth in systems and services sales, with a particular focus on marketing and selling value-added solutions to our customers, on commercial execution, and on carrying out Accuray's mission for the benefit of countless customers and patients."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, expectations regarding the Company's new Chief Commercial Officer and ability to strengthen commercial performance. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 17, 2026, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact
Steve Monroe
Vice President, Financial Planning & Analysis - Accuray
smonroe@accuray.com
Investor Contact
Aman Patel, CFA
Investor Relations, ICR-Westwicke
aman.patel@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-appoints-paul-miele-as-senior-vice-president-and-chief-commercial-officer-302733399.html
SOURCE Accuray Incorporated